Anti-Tumor Necrosis Factor Alfa (TNF-a)

Adjudication Rule

Table of content

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Scope</th>
<th>Adjudication Policy</th>
<th>Adjudication examples</th>
<th>Denial codes</th>
<th>Appendices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 1</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 3</td>
</tr>
</tbody>
</table>

Abstract

For Members

Tumor necrosis factor (TNF-alpha) is a protein molecule that promotes the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders. These disorders are sometimes treated by using Anti-TNF alpha drugs.

Anti-tumor necrosis factor drugs are a class of drugs that have been used worldwide to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, Crohn's colitis, ankylosing spondylitis and psoriasis. These drugs are able to reduce inflammation and stop disease progression.

Serious side effects that have been most extensively related to TNF blockers include lymphoma, infections (sometimes severe like tuberculosis, septicemia), congestive heart failure, and injection site reactions.

For Medical Professionals

This Adjudication Rule highlights the coverage of Anti-Tumor Necrosis Factor Alfa (Anti TNF-α) which includes Adalimumab, Infliximab, Simponi and Etanercept.

They are indicated for the management of:

- Severe Rheumatoid Arthritis
- Severe Psoriatic Arthritis
- Severe ankylosing spondylitis
- Crohn’s disease (except Etanercept)
- Plaque psoriasis
- Juvenile Idiopathic Arthritis
- Ulcerative Colitis

Daman covers Anti-TNF alpha for all the above mentioned diagnosis, when prescribed by a physician of appropriate specialty, and as per policy terms and conditions for each health insurance plan administered by Daman.
Anti-Tumor Necrosis Factor Alfa (TNF-α)

Scope

The scope of this guideline is to highlight the coverage of Anti-Tumor Necrosis Factor Alpha (Anti-TNF-α) which includes Adalimumab, Infliximab, Simponi and Etanercept.

1. Adalimumab (Humira®) is available as subcutaneous injection (no need for patient admission)
2. Infliximab (Remicade®) is available as lyophilisated powder for Intravenous injection (at least 120 min are needed to administer this drug)
3. Etanercept (Enbrel®) is available as subcutaneous injection (no need for patient admission)
4. Golimumab (Simponi®) is available as subcutaneous injection (no need for patient admission) for adults to be given once a week.

Non-Coverage

Anti-TNF-α is not covered for Visitor’s Plan. Coverage of these drugs for Abu Dhabi plan depends on HAAD basic drug list effective at the time of prescription.

Payment and Coding Rules

Please apply HAAD payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

Adjudication Policy

Eligibility / Coverage Criteria

All the above-mentioned Anti-TNF medications (Humira®, Simponi®, Remicade® and Enbrel®) are covered for all Daman plans, except for Visitor’s plan. Coverage of these drugs for Abu Dhabi plan depends on HAAD basic drug list effective at the time of prescription.

They are indicated for the management of:

- Severe Rheumatoid Arthritis
- Severe Psoriatic Arthritis
- Severe ankylosing spondylitis
- Crohn’s disease (except Etanercept)
- Plaque psoriasis
- Juvenile Idiopathic Arthritis
- Ulcerative Colitis

Daman will cover ANTI-TNF-α for the above-mentioned diagnosis when prescribed by a physician of appropriate specialty. They are used only after the failure of other management plans. Severity of those cases should be proven and documented properly.

Food and Drug administration stated that Anti-TNF-α can lead to serious infections (like; TB and malignancy), and the patient should be fully aware about both of these serious side effects before taking the medication.

Denial codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNEC-003</td>
<td>Service is not clinically indicated based on good clinical practice</td>
</tr>
<tr>
<td>NCOV-003</td>
<td>Service(s) is (are) not covered</td>
</tr>
<tr>
<td>CODE-010</td>
<td>Activity/Diagnosis inconsistence with clinician specialty</td>
</tr>
<tr>
<td>MNEC-004</td>
<td>Service is not clinically indicated based on good clinical practice, without additional diagnosis/activities.</td>
</tr>
</tbody>
</table>

Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.
Anti-Tumor Necrosis Factor Alfa (TNF-a)

Appendices

A. References

2. British society for Rheumatology Guidelines for TNF Alpha Inhibitors
3. Martindale: the complete Drug Reference
6. FDA Warnings for Aug,2004

B. Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01-07-13</td>
<td>V 2.0: New template Added: coverage information of Humira in Ulcerative Colitis</td>
</tr>
<tr>
<td>01-04-14</td>
<td>1. V 3.0 2. Restored original effective date 3. Disclaimer updated as per system requirements 4. Added coverage for Golimumab (Simponi®)</td>
</tr>
</tbody>
</table>